3:37 PM
 | 
Sep 12, 2018
 |  BC Extra  |  Company News

Zai Lab gets Chinese rights to Novocure's oncology tech

Novocure Ltd. (NASDAQ:NVCR) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to oncology platform Tumor Treating Fields in China, including Hong Kong and Macau, and Taiwan.

Novocure will receive $15 million up front and is eligible for $78 million in development, regulatory and commercial milestones, plus tiered royalties.

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >